Vertaling van "annual report and conform with international " (Nederlands → Frans) :

The Group’s principal accounting policies are set out in note 1 to the Consolidated Financial Statements in the 2009 Annual Report and conform with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.
Les principales normes comptables appliquées par le Groupe sont exposées à la note 1 des Comptes consolidés figurant dans le Rapport annuel 2009 et satisfont aux normes dites International Financial Reporting Standards (IFRS) établies par l’International Accounting Standards Board.

The principal accounting policies of Novartis are set out in note 1 to the consolidated financial statements in the 2008 Annual Report and conform with International Financial Reporting Standards (IFRS).
Les principales normes comptables appliquées par Novartis sont exposées dans l’annexe 1 aux comptes consolidés du Groupe figurant dans le Rapport annuel 2008 et satisfont aux normes International Financial Reporting Standards (IFRS).

The principal accounting policies of Novartis are set out in note 1 to the Consolidated Financial Statements in the 2008 Annual Report and conform with International Financial Reporting Standards (IFRS).
Les principales normes comptables appliquées par Novartis sont exposées dans l’annexe 1 aux comptes consolidés du Groupe figurant dans le Rapport annuel 2008 et satisfont aux normes International Financial Reporting Standards (IFRS).

The Group’s principal accounting policies are set out in note 1 to the Consolidated Financial Statements in the 2008 Annual Report and conform with International Financial Reporting Standards (IFRS).
Les principales normes comptables appliquées par le Groupe sont exposées dans l’annexe 1 aux Comptes consolidés figurant dans le Rapport annuel 2008 et satisfont aux normes International Financial Reporting Standards (IFRS).

The Group’s principal accounting policies are set out in note 1 to the Consolidated Financial Statements in the 2009 Annual Report and conform with International Financial Reporting Standards (IFRS).
Les principales normes comptables appliquées par le Groupe sont exposées à la note 1 des Comptes consolidés figurant dans le Rapport annuel 2009 et satisfont aux normes International Financial Reporting Standards (IFRS).

These Condensed Interim Consolidated Financial Statements for the three- and sixmonth periods ended June 30, 2009, were prepared in accordance with International Accounting Standard 34 Interim Financial Reporting and accounting policies set out in the 2008 Annual Report published on January 28, 2009.
Les comptes intermédiaires consolidés simplifiés pour les périodes de trois et six mois se terminant le 30 juin 2009 ont été établis conformément à la norme comptable internationale 34 Information financière intermédiaire et aux normes comptables décrites dans le rapport annuel 2008 publié le 28 janvier 2009.

These condensed consolidated financial statements for the three-month quarterly and the 12-month periods ended December 31, 2008, were prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” and accounting policies set out in the 2008 Annual Report published on January 28, 2009.
Les comptes consolidés simplifiés pour le trimestre et la période de douze mois se terminant le 31 décembre 2008 ont été établis conformément à la norme comptable internationale 34 concernant l’information financière intermédiaire (IAS 34 « Interim Financial Reporting ») et aux normes comptables décrites dans le rapport annuel 2008 publié le 28 janvier 2009.

Annual report 2007” originated as a trainee’s report by Ann Eeckhout, head of the Communication & Scientific Support service, with the valuable cooperation of colleagues from the FAMHP.
Annual report 2007” originated as a trainee’s report by Ann Eeckhout, head of the Communication & Scientific Support service, with the valuable cooperation of colleagues from the FAMHP.

The report on the Agency’s first year of work was naturally focused on the establishment and transition of the organisation. This second annual report is devoted to the further development of the FAMHP, with a range of examples of the numerous positive activities which perfectly reflect the great diversity of its work.
The report on the Agency’s first year of work was naturally focused on the establishment and transition of the organisation. This second annual report is devoted to the further development of the FAMHP, with a range of examples of the numerous positive activities which perfectly reflect the great diversity of its work.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.